$PRTA

SCULLY WILLIAM P purchased $471K of PRTA

SCULLY WILLIAM P purchased 50,000 shares of PROTHENA CORP PUBLIC LTD CO (PRTA) at $9.43 ($0.47M total) on 2026-06-02.

Original reporting
SEC EDGAR · SCULLY WILLIAM P
Published Jun 3, 2026, 4:41 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 4:42 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRTA
Bullish
medium confidence
Mentioned
$PRTA
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRTABullishLow
01

Why it matters

The disclosure provides incremental sentiment information (insider ownership increase) but does not introduce new company-specific fundamentals such as trial results, regulatory actions, or partnership updates.

02

Market read

Traders may treat as a mild positive sentiment/flow datapoint for PRTA, with limited standalone catalyst value.

03

What to watch

The article notes no pre-arranged 10b5-1 plan; traders may still need to check whether the buyer’s broader pattern (prior Form 4s) supports a sustained accumulation thesis.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-03; purchase dated 2026-06-02 (post-close disclosure window).

Background

This is an SEC Form 4 insider transaction disclosure (10% owner open-market purchase) for Prothena Corp. plc.

Company-level read

Ticker impact

$PRTABullishMedium confidence
Context

Prothena’s 10% owner William P. Scully bought 50,000 shares open-market on 2026-06-02, disclosed via SEC Form 4.

Expected impact

Likely limited/short-lived positive drift; any impact is more sentiment/flow-related than catalyst-driven.

Evidence & confidence

The filing reports an ownership increase (direct purchase) with no new operational, clinical, or deal information; insider buys can support sentiment but are rarely standalone price catalysts.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide regulatory/clinical development.

None indicated; US-listed biotech insider transaction only.

None indicated beyond PRTA-specific sentiment/positioning.

Counterpoint

Insider purchases can be routine (tax/portfolio rebalancing) and may not reflect a new view on upcoming clinical or commercial milestones.

Key entities

  • PROTHENA CORP PUBLIC LTD CO

    Subject of the Form 4 insider transaction; 10% owner purchased shares open-market.

  • SCULLY WILLIAM P

    10% owner who purchased 50,000 shares at $9.4260 on 2026-06-02.

Related articles

$PRTAMed

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

Prothena (PRTA) reported Q2 2026 adjusted loss per share of 32 cents, narrower than the Zacks estimate of a 39-cent loss. Revenues were $1.01 million versus $4.4 million a year earlier, mainly collaboration revenue from Bristol Myers Squibb (BMY) for PRX019. Prothena had $330.3 million cash, no debt, and reaffirmed 2026 net cash use guidance of $18-$23 million.

$PRTAMed

PROTHENA CORP PUBLIC LTD CO (PRTA): Results of Operations and Financial Condition

PROTHENA CORP PUBLIC LTD CO (PRTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026earningsre.htm EX-99.1 Document Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2026 Financial Results an d Business Highlights • Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provide